CalciMedica

CALC · NASDAQ

$1.07+$0.045 (+4.41%)TodayMarket closed · Oct 20, 7:49 PM ET

Prev close $1.02

CALC analyst rating

BuyConsensus of 3 analysts over the last 12 months. 67% rate it a buy.

Strong buy0
Buy2
Hold1
Underperform0
Sell0

12-month price target · 4 analysts

Average $38.25 (+3491.5% upside)

Low: $30.30
Now: $1.07
High: $47.25

Upgrades and downgrades

The latest rating actions, newest first

CALC analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Guggenheim	Aug 20, 2026	Initiates	Buy	$9.00	66%
Oppenheimer	Mar 5, 2026	Maintains	Outperform	$20.00 → $10.00	45%
HC Wainwright & Co.	Jan 29, 2026	Downgrade	Buy → Neutral	—	40%

The case for and against

Updated Oct 31, 2025

Bull case

CalciMedica Inc's clinical-stage therapeutic candidate, Auxora, has demonstrated significant promise in treating acute kidney injury (AKI) associated with severe COVID-19 pneumonia, with a notable 62.7% relative reduction in mortality at day 30 among patients treated with Auxora compared to placebo. This positive outcome from the post-hoc analysis of the CARDEA trial supports confidence in the ongoing Phase 2 KOURAGE study, which aims to further evaluate the efficacy of Auxora in similar patient populations. The anticipated clinical benefits of Auxora, including reduced dialysis needs, lower mortality rates, and improved renal recovery, position the company favorably for potential adoption in the market, reflecting a positive outlook for CalciMedica's future.

Bear case

CalciMedica Inc has faced significant challenges, including failed or inconclusive clinical trials and difficulties in securing adequate funding, which heighten the risk of dilutive capital raises. In its recent 1Q25 financial results, the company reported an earnings per share (EPS) of ($0.36), which fell short of estimates and consensus expectations, indicating ongoing financial instability. The company's reliance on the success of its product candidate, Auxora, to navigate critical clinical and funding hurdles suggests a precarious position going forward.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.